Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.

Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW.

Adv Clin Chem. 2016;77:77-101. doi: 10.1016/bs.acc.2016.06.002. Epub 2016 Jun 30. Review.

PMID:
27717419
2.

Glycoprotein 2 antibodies in Crohn's disease.

Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K.

Adv Clin Chem. 2013;60:187-208. Review.

PMID:
23724745
3.

Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges.

Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW.

Clin Chem Lab Med. 2014 Apr;52(4):483-94. doi: 10.1515/cclm-2013-0801. Review.

4.

Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.

Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K.

Gut. 2009 Dec;58(12):1620-8. doi: 10.1136/gut.2008.162495. Epub 2009 Jun 22.

PMID:
19549613
5.

Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.

Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K.

Autoimmun Rev. 2011 Dec;11(2):143-8. doi: 10.1016/j.autrev.2011.09.004. Epub 2011 Sep 29. Review.

PMID:
21983481
6.

Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].

Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL.

J Crohns Colitis. 2015 Aug;9(8):659-68. doi: 10.1093/ecco-jcc/jjv087. Epub 2015 May 12.

PMID:
25968583
7.

Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.

Michaels MA, Jendrek ST, Korf T, Nitzsche T, Teegen B, Komorowski L, Derer S, Schröder T, Baer F, Lehnert H, Büning J, Fellerman K, Sina C.

Inflamm Bowel Dis. 2015 Dec;21(12):2864-72. doi: 10.1097/MIB.0000000000000564.

PMID:
26273818
8.

Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.

Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, Bogdanos DP.

Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/640835. Epub 2012 Oct 17.

9.

Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.

Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, Büttner T, Porstmann T, Porstmann S, Liedvogel B, Bogdanos DP, Laass MW, Conrad K.

Clin Chim Acta. 2011 Apr 11;412(9-10):718-24. doi: 10.1016/j.cca.2010.12.029. Epub 2010 Dec 31.

PMID:
21195704
10.

Serological studies in inflammatory bowel disease: how important are they?

Papp M, Lakatos PL.

Curr Opin Gastroenterol. 2014 Jul;30(4):359-64. doi: 10.1097/MOG.0000000000000076. Review.

PMID:
24811052
11.

Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.

Komorowski L, Teegen B, Probst C, Aulinger-Stöcker K, Sina C, Fellermann K, Stöcker W.

J Crohns Colitis. 2013 Nov;7(10):780-90. doi: 10.1016/j.crohns.2012.10.011. Epub 2012 Nov 7.

PMID:
23140841
12.

The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.

Somma V, Ababneh H, Ababneh A, Gatti S, Romagnoli V, Bendia E, Conrad K, Bogdanos DP, Roggenbuck D, Ciarrocchi G.

Gastroenterol Res Pract. 2013;2013:683824. doi: 10.1155/2013/683824. Epub 2013 May 15.

13.

Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.

Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P, von Arnim U, Malfertheiner P, Forbes A, Conrad K, Laass MW.

BMC Gastroenterol. 2012 Aug 6;12:102.

14.

Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.

Werner L, Sturm A, Roggenbuck D, Yahav L, Zion T, Meirowithz E, Ofer A, Guzner-Gur H, Tulchinsky H, Dotan I.

J Crohns Colitis. 2013 Dec;7(11):e522-32. doi: 10.1016/j.crohns.2013.03.009. Epub 2013 Apr 30.

PMID:
23639628
15.

Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

Sartor RB.

Gastroenterol Clin North Am. 1995 Sep;24(3):475-507. Review.

PMID:
8809232
16.

Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.

Roggenbuck D, Vermeire S, Hoffman I, Reinhold D, Schierack P, Goihl A, von Arnim U, De Hertogh G, Polymeros D, Bogdanos DP, Bossuyt X.

Clin Chem Lab Med. 2015 Aug;53(9):1349-57. doi: 10.1515/cclm-2014-0238.

PMID:
25411995
18.

Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis?

Wen Z, Fiocchi C.

Clin Dev Immunol. 2004 Sep-Dec;11(3-4):195-204. Review.

19.

Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.

Liaskos C, Spyrou V, Roggenbuck D, Athanasiou LV, Orfanidou T, Mavropoulos A, Reinhold D, Rigopoulou EI, Amiridis GS, Billinis C, Bogdanos DP.

Autoimmunity. 2013 Sep;46(6):388-94. doi: 10.3109/08916934.2013.786047. Epub 2013 May 2.

PMID:
23638886
20.

Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I.

World J Gastroenterol. 2014 Feb 7;20(5):1192-210. doi: 10.3748/wjg.v20.i5.1192. Review.

Supplemental Content

Support Center